Contineum Therapeutics (CTNM) Cash from Financing Activities (2023 - 2026)

Contineum Therapeutics' Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $129000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 437.5% year-over-year to $129000.0; the TTM figure through Mar 2026 stood at $112.8 million (up 3.44% YoY), while the FY2025 annual figure was $112.7 million, up 3.38% from the prior year.
• Cash from Financing Activities was $129000.0 for Q1 2026 at Contineum Therapeutics, down from $93.5 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $108.4 million in Q2 2024 to a low of -$617000.0 in Q1 2023.
• Historically, Cash from Financing Activities has averaged $21.4 million across 4 years, with a median of $129000.0 in 2026.
• Biggest YoY gain for Cash from Financing Activities was 146861.54% in 2025; the steepest drop was 99.92% in 2025.
• A 4-year view of Cash from Financing Activities shows it stood at -$321000.0 in 2023, then surged by 300.0% to $642000.0 in 2024, then surged by 14458.41% to $93.5 million in 2025, then sank by 99.86% to $129000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $129000.0 (Q1 2026), $93.5 million (Q4 2025), and $19.1 million (Q3 2025), per Business Quant data.